Key facts
- InduPro’s last known valuation is $124.5M (Jun 2024).
- It has raised $85.0M across 2 recorded rounds; the latest was Later Stage VC ($77.0M) in Aug 2026.
- Notable investors include The Engine, Emerson Collective, Euclidean Capital, Eli Lilly, MRL Ventures Fund — 8 tracked in total.
- Status: Privately Held (backing).
Leadership
- Prakash RamanChief Executive Officer
- Scott LesleyPresident & Chief Scientific Officer
- Amanda J. RedigChief Medical Officer
- Sally JohnsonChief People Officer
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for InduPro
Funding rounds
2 roundsAbout InduPro
Operator of a biopharma company intended to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates. The company's platform integrates inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics, enabling patients with therapies through novel cell-surface platform technologies.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2022
- Employees
- 49
- Website
- induprotx.com/
- Ownership
- Privately Held (backing)
InduPro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InduPro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InduPro in its N-PORT filings yet. We sweep new filings monthly.